Overall, MajesTEC-3 signals a meaningful step forward for combination bispecific therapies in multiple myeloma, while ...

Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, combination-based strategies—particularly for patients with BTK ...

Please provide your email address to receive an email when new articles are posted on . Researchers observed responses at all dose levels, with the recommended phase 2 regimen linked to durable ...

A combination in options trading is a strategy involving different calls and puts on the same asset. Learn how these ...

LBA-6: Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients (Pts) with ...

Patients with relapsed or refractory multiple myeloma experienced a benefit after receiving Xpovio in combination with Darzalex, Velcade and the steroid dexamethasone. Recent study findings showed ...

Scientists have created a prototype test that can predict which drug combinations are likely to work for cancer patients in as little as 24 to 48 hours. Their cutting-edge technique uses artificial ...

ERAS-007, a potential best-in-class ERK1/2 inhibitor, will be evaluated initially in combinations that could address over half of patients with colorectal cancer SAN DIEGO, Sept. 22, 2021 (GLOBE ...